Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective

Value Health. 2014 Nov;17(7):A347. doi: 10.1016/j.jval.2014.08.710. Epub 2014 Oct 26.

Authors

M Charokopou¹, H Vioix², L A Eddowes³, M Griffiths³, B G Verheggen¹, Z Gabriel², K Tolley⁴

Affiliations

¹ Pharmerit International, Rotterdam, The Netherlands.
² AstraZeneca UK Ltd., Luton, UK.
³ Costello Medical Consulting Ltd., Cambridge, UK.
⁴ Tolley Health Economics Ltd., Buxton, Derbyshire, UK.

PMID: 27200660
DOI: 10.1016/j.jval.2014.08.710

No abstract available